ICCM

ICCM

USD

IceCure Medical Ltd. Ordinary Shares

$0.728+0.000 (0.069%)

Reaalajas hind

Healthcare
Meditsiiniseadmed
Iisrael

Hinnagraafik

Loading Chart...

Põhinäitajad

Turunäitajad
Ettevõtte fundamentaalnäitajad
Kauplemisstatistika

Turunäitajad

Avatud

$0.728

Kõrge

$0.740

Madal

$0.714

Maht

0.13M

Ettevõtte fundamentaalnäitajad

Turukapitalisatsioon

50.2M

Tööstusharu

Meditsiiniseadmed

Riik

Israel

Kauplemisstatistika

Keskmine maht

1.68M

Börs

NCM

Valuuta

USD

52 nädala vahemik

Madal $0.534Praegune $0.728Kõrge $1.66

Seotud uudised

PR Newswire

IceCure's ProSense® Showcased at TME Fall Summit: "Take the Lead in Breast Cancer Care" Roundtable Highlighting Cryoablation Advances

IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that...

Vaata rohkem
IceCure's ProSense® Showcased at TME Fall Summit: "Take the Lead in Breast Cancer Care" Roundtable Highlighting Cryoablation Advances
Analyst Upgrades

HC Wainwright & Co. Maintains Buy on Icecure Medical, Raises Price Target to $2.5

HC Wainwright & Co. analyst Yi Chen maintains Icecure Medical with a Buy and raises the price target from $2 to $2.5.

Vaata rohkem
HC Wainwright & Co. Maintains Buy on Icecure Medical, Raises Price Target to $2.5
PR Newswire

IceCure Medical's ProSense® Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in Giving Women with Breast Cancer Minimally Invasive Care

The U.S. Food and Drug Administration ("FDA") has granted marketing authorization for ProSense®, a minimally invasive cryoablation treatment for...

Vaata rohkem
IceCure Medical's ProSense® Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in Giving Women with Breast Cancer Minimally Invasive Care
PR Newswire

IceCure Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above

IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that...

Vaata rohkem
IceCure Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above

Püsi kursis

Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.